ArticleRSC advances2026
Acid-responsive metal organic frameworks with photothermal effects for osteoarthritis multiple therapy.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early osteoarthritis (OA) with reversible ability appears to lack features other than intense acute inflammation. Herein, we developed a pH-responsive metal organic framework (MOF) system based on phenylboronic acid (PBA) and O-hydroxyl pH-dependent reversible switches. Click chemistry enables a simple and environmentally friendly synthesis process and sensitive drug release procedure. Nanoparticles possess excellent photothermal conversion capabilities that enable thermal interventions alongside sustained drug release, thereby treating early OA in multiple ways. The results indicate that nanoparticles have high drug-loading capacity and can respond to the weakly acidic conditions in the OA microenvironment to release ellagic acid (EA) gradually. It can also significantly reduce inflammatory reactions induced by IL-1β. The high effectiveness of this compound therapy is comprehensively demonstrated by both
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.